Try our Advanced Search for more refined results
Life Sciences - May, 2019
329 articles
- J&J Rep Grilled On 'Low Abuse Potential' Opioid Claim
- Heritage Pharma Admits Price Fixing, Aids DOJ Probe
- 4 Firms Break From Pack In Robust May For IPOs
- Claims Rep For J&J Talc Supplier Survives Removal Bids
- From Prison, Shkreli Files $30M Suit Over Retrophin Ouster
- Health Hires: Morgan Lewis, Manatt Phelps, Dovel Tech
- FDA Focus: What Covington's Practice Chair Is Watching
- Pharma Co. Gets Suit Over $61M Offering Sent To Mass.
- J&J Hit With $300M Punitive Damages Verdict In NY Talc Trial
- The Role Of Risk Aversion In Reverse-Payment Agreements
- LA County Sues Monsanto, Pfizer Unit Over PCB Pollution
- J&J Targeted Docs To Push Fentanyl Patch, Okla. Judge Hears
- DOJ Requires Divestitures In $6.8B Amcor-Bemis Tie-Up
- Dilworth Paxson Adds Ex-Reed Smith IP Atty In NJ, Pa.
- Pharma Co., Founder To Pay $7M Over Aspirin Drug Fraud
- NJ AG Latest To Go After Sacklers Over Opioid Crisis
- Deals Rumor Mill: Hansoh, CBS-Viacom, Gannett
- TridentUSA Lender Says Loan Fight Breaks Restructuring Deal
- Novum Keeps Sale Option Open As Ch. 11 Plan Talks Progress
- Hatch-Waxman Presuit Considerations For Generics: Part 2
- 'Ashamed' NECC Pharmacist Spared Prison In Meningitis Case
- Motherhood & Making Partner: The View From 2 BigLaw Moms
- J&J Glossed Over Opioid Dangers, Okla. Judge Hears
- J&J, Colgate Expert Defends Talc Products As Trial Nears End
- Caster Semenya Appeals Testosterone Ruling To Swiss Court
- 2 Firms Named Lead Counsel In Trevena Stock-Drop Suit
- 5 Attorneys On Being The Only Woman In The Room
- Millennials Are Pushing Back Against Law Firm Sexism
- Toy Race Car Co. Owner Accused Of $4M Aspirin Drug Fraud
- Insurer Says $3.3M TCPA Deal Excluded From Lab's Policy
- Ex-NECC Pharmacist Gets 2.5 Years For Role In Drug Fraud
- University Of California Gets 5th CRISPR Patent
- Allergan Looks To Have Shire's Eye Drug Suit Tossed Again
- Law Profs Back Bid For High Court Input In ERISA Suit Venue
- Breaking Down The Proposal For A Patent Eligibility Revamp
- UFC Fighter Wins $27.5M Over Mislabeled Supplement
- Drugmaker Aqua Will Pay $3.5M To Settle Kickback Claims
- And Now A Word From The Panel: Why Not Just Arbitrate?
- Shareholders Say Boston Is Best For $555M Perrigo Fraud Suit
- Hatch-Waxman Presuit Considerations For Generics: Part 1
- Attys In $11.9M Thoratec Heart Device Deal Seek $2.9M In Fees
- Last-Minute Deals Delay Argos' Ch. 11 Confirmation
- Pomerantz To Lead Securities Suit Against WuXi
- How FDA Is Refreshing Its Recall Readiness Guidance
- 3 Law Firm Business Tactics To Support A Niche Practice
- Prosthetics Co. Can't Shirk Atty Fees In Patent Dispute
- FDA Rolls Eyes At Drug Co.'s 'Financial Distress' Claim
- Atty Fees Aren't USPTO 'Expenses': Fed. Circ. Bar To Justices
- The Best Law Firms For Female Partners
- In The March Toward Parity, Law Firms Fall Behind
- Can You Spot The Gender Disparity? A Guide To Implicit Bias
- J&J's 2nd Mistrial Bid 'Ridiculous,' Calif. Judge Says
- Ancestry.com Gets Health Info Privacy Suit Sent To Arbitration
- Blue Cross' Antitrust Suit Belongs In NJ, Janssen Says
- Reed Smith Atty's Widow Can't Take GSK Fight To High Court
- Attys Behind Syphilis Study Suit Fight Sanctions Bid
- Pharmaceutical Antitrust Legislation To Watch
- J&J Called Architect Of Opioid Crisis As Epic Trial Begins
- New Opinions Highlight 3 FMLA Issues To Avoid
- Lessons From Red Yeast Rice May Inform FDA's Path For CBD
- The Best Law Firms For Female Attorneys
- Glass Ceiling Slow To Break For Female Attys In 2018
- What 12 Gender Bias Complaints Say About BigLaw
- Teva Settles Okla. Opioid Case For $85M Just Before Trial
- J&J Can't Get New Trial After $29.5M Talc Verdict
- Chancery Saves Ligand From $3.75B Loss On Bond Bungle
- Pharma Co. Inks $22M Deal Ending Opioid Reporting Claims
- Meet The Attorneys Facing Off In The Oklahoma Opioid Trial
- McKesson Enjoyed 'Massive Insider Trading Binge,' Suit Says
- What Attys Need To Know As Landmark Opioid Trial Begins
- UK Litigation Roundup: Here's What You Missed In London
- FCA Suit Against Ex-Aegerion Execs Is Likely To Live On
- Class Attys Get $1M Fees In TCPA Deal Over Unwanted Faxes
- Real-Life Lessons For Lawyers From 'Game Of Thrones'
- Biopharma Co. Advicenne Plans Cross-Listing In Brussels
- 5 Tips To Help Your Summer Associates Succeed
- 'Roundup Cocktail' Argument A Potent Threat After $2B Award
- Aegerion Pharma's Interim Ch. 11 Cash Request Irks Judge
- J&J, Colgate Duck Sanctions After Expert Blows Past Order
- FTC Says Likely Pay-For-Delay Deals Are Down
- BioChemics Can't Revive SEC Probe Coverage Bid At 1st Circ.
- 2nd Circ. OKs $2.7M In Fees From BioScrip Investor Deal
- 2 Biotech Cos. Raise $111M Combined In Low-Priced IPOs
- Fountain Healthcare's Third Fund Hits €118M First Close
- Chemical Co. Misled Investors Before IPO, Investor Suit Says
- Avenatti Booted From Class Counsel In Surgical Gown Suit
- Keys To Communicating A Law Firm's Mission
- Endo Investors Seek Class Cert. In Opioid Stock-Drop Suit
- What's Ahead For FDA Regulation Of Dietary Supplements
- New Views On Statistical Significance Affect Expert Testimony
- Kenneth Feinberg Tapped To Mediate Monsanto Roundup MDL
- TridentUSA Ch. 11 Lender Fight Over Priority Claims Heats Up
- Chancery Finds Ex-CEO In Contempt In Biopharma IP Suit
- Judge Grows Weary Of Infighting In J&J Talc Supplier's Ch. 11
- Draft Patent Eligibility Bill Would Undo Alice, Mayo
- GSK, Teva Urge 3rd Circ. To Nix Lamictal Class Cert.
- Pharmas Want Verdict Axed To Settle IP, Antitrust Disputes
- Amgen Says Rival Used Trade Secrets To Poach 14 Reps
- Ex-Olympus Exec Ducks Prison In Tainted Scopes Case
- Nivea Maker Can't Duck Suit Claiming Lotion Was A Drug
- Amgen Lobs $167M Bid For Danish Biopharma Nuevolution
- Purdue's Sacklers Pushed Opioids To Get Rich, New Suits Say
- Solicitor General Tells Justices To Skip Roche Patent Appeal
- Second Atty Sanctioned For Monsanto MDL Opening Remark
- House Lawmakers Joust Over Drug Pricing Transparency Bills
- Torrent Pharma Accused Of Distributing Tainted Pills
- J&J Unit Hit With Antitrust Suit Over 'Sham' Zytiga Patent
- CVS Defends Contract Counterclaim In Sentry Antitrust Suit
- Ex-J&J Safety Exec Warned Against Speechifying In Talc Trial
- Feds' Rebate Switch May Cost Mallinckrodt $600M, Suit Says
- Grant & Eisenhofer, Wolf Popper To Lead AbbVie Records Suit
- J&J Hit With $25M NY Talc Verdict, But Wins Trial In SC
- J&J Tells 7th Circ. Missing FDA Evidence Dooms $20M Verdict
- How Lawyers Can Help Save The Planet
- Time To Create A Viable Path To Biosimilar Interchangeability
- Justices Lay Out Failure To Warn 'Clear Evidence' Standard
- Aegerion Files Ch. 11, Plans $400M Sale To Amryt Pharma
- Merck Buys Peloton Therapeutics For $1.05B Ahead Of IPO
- Pradaxa User Wins $542K Verdict In Conn. Bellwether Trial
- USPTO Tells Justices Law Is Clear-Cut On Win-Or-Lose Fees
- Houston Pharma Co. To Recall Contaminated And Weak Drugs
- J&J Loses Mistrial Bid Over Curious Judge
- Dexcom Asks Fed. Circ. To Nix $1.3M Fee Award In IP Row
- Drugmaker, Retailers Strike Deal In Loestrin Antitrust MDL
- Alcor Looks To Overturn $6.5M Blood Testing IP Verdict
- Union Of Tech, Life Sciences And Health Care Is Here To Stay
- High Court Won't Hear Orexigen Securities Fraud Suit
- Justices Say Judges, Not Juries, Must Decipher FDA Rules
- A Potential New Fight Over FTC's 13(b) Authority
- Texas Judge Backs Broad DOJ Authority To End FCA Suits
- Orexigen Cleared For Wind Down After Del. Ch. 11 Confirmed
- CVS Ditches False Ad Suit Over Joint Health Pills
- Dysfunction Leads Del. Chancery To Dissolve Pharma Co.
- House Passes Bill To Lower Drug Prices, Bolster ACA
- 8 Firms Steer 5 IPOs Topping $1B Led By Diamondback Unit
- How Supreme Court Conservatives Have Shaped The FCA
- IRS Should Use Tax Law To Combat The Opioid Epidemic
- J&J Hit With $80M Verdict In Philly Mesh Case
- American Researchers To Be Added To Nobel-Related Patents
- FTC Must Tackle Anti-Competitive Drug Rebate Practices
- Dorsey & Whitney Adds Veteran Product Liability Litigator
- Zetia Buyers Demand Info On Generics In Pay-For-Delay Suit
- Inside The New FCA Cooperation Credit Guidelines
- Key Takeaways From Roundup Verdicts So Far
- A Chat With Gilead Sciences Legal Ops Leader Gary Tully
- Trump Ditches New Negotiating Powers For Medicare Part D
- CDC's HIV Prevention Patents Invalid, Gilead CEO Tells House
- United, Humana Say Classes Can't Carve Up Generic Awards
- Blood Clot Drug Buyers Must Redo Class Cert. Bid
- Ill. Court Kills Shunt Patent Suit That Targeted Hundreds
- Essure Users Fight To Keep Bayer Injury Suits Alive In Calif.
- 5th Circ. Revives MD's Securities Suit Against Ex-Biz Partner
- Pa. Justices Suggest Juries Should Decide Risperdal Time Bar
- New Leader Can't Save Biotech IPO Suit, Judge Rules
- FDA Response To Cannabidiol Confusion Is Slow And Steady
- Deals Rumor Mill: Helaba-DekaBank, Pret A Manger, Takeda
- 5 More States Target Purdue Pharma Over Opioid Marketing
- Allergan Wins Just $48.5K At Trial Over Imprimis False Ads
- Pyrinas-Aeneas JV Eyes $120M Biotech Real Estate Fund
- $2B Roundup Verdict Likely Won't Hold Up, Legal Pros Say
- Imprimis Owes Rival Allergan False Ad Drug Profits, Jury Told
- North Dakota To Appeal Dismissal Of Purdue Opioid Suit
- DLA Piper Announces New Artificial Intelligence Practice
- Ixchel To 9th Circ. In Biogen Row: Companies Are People, Too
- Insurers Flag Special Counsel In Imerys Ch. 11
- SEC's Relaxed Audit Rules Likely To Get Mixed Reviews
- Interest Groups Slam Pa. Ruling Over Cancer-Pesticide Link
- Fed. Circ. Kills 2 Patents On Horizon Pain Drug Vimovo
- USPTO Leaves It Up To Applicants To Flag Patent Term Errors
- Fla. Blue Says DaVita Charity Scheme Cost Insurer Millions
- Gene Sequencing Co. ArcherDX Scores $60M Funding Round
- Why I Became A Lawyer: Completing The Journey Home
- 3 Firms Steer New Takeda, Frazier Biopharma Venture
- NJ Justices Deny Merck Shareholder's Docs Request
- Gilead Built HIV Drug Empire On 'No Generic' Deals, Suit Says
- Pa. AG Says Purdue Buried Doctors In False Painkiller Claims
- Fed. Circ. Backs PTAB Ax Of J&J Prostate Cancer Drug Patent
- What Fed. Circ. False Ad Ruling Means For Section 337 Claims
- Boehringer Waves White Flag In Humira Patent Battle
- Roche Again Delays $4.3B Spark Buy Amid Regulatory Review
- Diabetes-Focused Biotech Prices $40M IPO Well Below Range
- J&J Hid Asbestos In Talc For Years, Latest Jury Told In SC
- Fed. Circ. Backs Novartis In Kidney Cancer Drug Patent Case
- ViSalus, Class Spar Over Potential $925M Robocall Award
- Attys React To High Court FCA Statute Of Limitations Ruling
- Identity Politics: How Firms Seal The Deal After A Merger
- High Court Got It Right On FCA Time Limits
- No Health Supplement IP Infringement, Fed. Circ. Affirms
- 3 Biotech Firms Prime IPOs That Could Raise $285M Total
- The Dangers Of BigLaw's Merger-Happy Growth Strategy
- The Firms That Lost The Most Attorneys In 2018
- Some IP Boutiques Take Hit Amid Shifting Patent Landscape
- Challenges To Different Patents Not Serial, PTAB Says
- J&J, Teva Lose Last-Ditch Bids To Avoid Okla. Opioid Trial
- Allergan Says Asacol Buyers' Generic-Delay Suit Defective
- Lannett Hit With Del. Suit Over Generic-Drug Price-Fixing
- Teva A 'Consistent Participant' In Drug Price-Fixing, AGs Say
- Monsanto Hit With $2B Verdict In 3rd Roundup Trial
- Judging A Book: Wood Reviews 'The Making Of A Justice'
- New Biotech ElevateBio Brings In $150M From Investors
- Insys Faces $18M Bill For Final Stretch Of Founder's Trial
- High Court Extends Time Limit For Nonintervened FCA Cases
- Megafirms Drive Thirst For Tie-Ups As Firms Scale Up
- Law360 Reveals 400 Largest US Firms
- These Law Firms Keep Their Partnership Ranks Lean
- FDA Eases Way For Gold-Standard Biosimilars
- Gilead Must Face Bulk Of Patients' Suit Over HIV Drugs
- Texas Justices End Dallas Newspaper Defamation Suit
- Fresenius Beats Fired Worker's Age Discrimination Suit
- Reed Smith Nabs Ex-Baker McKenzie Arbitration Pro In NY
- FDA Draft Guidance On Medical Device Inspections Is Limited
- Ex-Abiomed Exec Asks 1st Circ. To Revive $5M Bonus Suit
- Steptoe Lures FDA Compliance Pro From Keller Heckman
- Loeb & Loeb-Led Blank Check Co. IPO Raises $100M
- Getting Out Of Legal Project Management Debt
- How The New FCA Cooperation Credit Guidelines Fall Short
- SEC Won't Take Action Against Ocular Over Eye Drug
- Bipartisan Bill Aims To Deem Pharma Tactics Anti-Competitive
- 7 Cos. Price IPOs Totaling $689M Led By Russian Job Biz
- Fenwick & West Adds Startup-Focused Orrick Benefits Atty
- J&J Can't Transfer 2,400 Talc Suits To Del. Fed. Court
- Iancu Tells Congress One Drug Can Deserve Many Patents
- Novartis Inks $5.3B Deal To Get Eye Drug From Takeda
- Ex-Abbott Researcher Can't Duplicate Termination Claims
- Perrigo Inks $750M Deal As Part Of Shift To Consumer Goods
- Nabriva Hit With Stock-Drop Suit Over FDA Drug Rejection
- Drug Cos. Call 'Blocking Patent' Rule An 'Existential Threat'
- Latham Steers Boston Scientific's $465M Spinal Device Deal
- 6 Ways To Keep Your Jury From Zoning Out
- House Unanimously Passes Bills On Drug Patent Listings
- FCA Cooperation Guidance Still Missing Key Details
- FDA 'Heatstick' OK Clouds Agency's Youth Vaping Campaign
- 'Punish' Monsanto With $1B Roundup Verdict, Calif. Jury Told
- 6 Highlights As Trump Demands Drug Prices In TV Ads
- BakerHostetler Fights 'Indefensible' DQ In Opioid MDL
- Bernstein Liebhard Gets Lead Spot In Alnylam Stock Drop Suit
- Fed. Circ.'s Mayo Interpretation Spot On, Clinic Says
- Walgreens Board Says It Reacted Quickly To Theranos Fraud
- Fed. Circ. Says Sandoz Biosimilars Don't Step On Amgen IP
- Merck Legally Denied Union Workers Day Off, NLRB Says
- Deals Rumor Mill: Novartis, Permira, Grab
- GTx Framed Oncternal Takeover As Acquisition, Investors Say
- Arnold & Porter Leads Pfizer Deal Worth Up To $810M
- 5 Ways To Enhance Patent Strategy With Data Analytics
- Ex-Purdue Prez Said Addicts Are Victimizers, Not Victims: Suit
- DOJ Unveils Cooperation Credit Checklist For FCA Targets
- Fed. Circ. Zeroes In On Holes In Prenatal Testing Patent
- Senate Committee Seems United On Drug Pricing Reform
- HHS Must 'Unscramble The Egg' On Billions In Drug Cuts
- Prosthetic Maker Must Unwind Acquisition, FTC Judge Says
- Bayer CropScience Says Fired Scientist Stole Trade Secrets
- Squire Patton Taps Ex-MoFo IP Vets With Drug Co. Experience
- Atty Must List Conflict Info Before Guiding Future Talc Claims
- Chemical Co. Wants Pension Claims Cut From ERISA Suit
- Express Scripts Class Can't Revive Anthem Disclosure Suit
- IP Trade Group Urges Justices To Ax 'Blocking Patent' Rule
- Biotech Trevi Nabs $70M In Revised IPO, Private Placement
- New Regs, New Tech Bring New Medical Device Cyber Liability
- Workers Can't Get Colgate Sanctioned Over 'Sham Witness'
- 5 Myths In Legal Crisis Communications
- Key Takeaways From New 2nd Circ. Pleading Standards
- Insys Jurors Say They Thought Execs Were Guilty Early On
- 1st Circ. Flips $34M FCA Award To New Whistleblower
- NJ Pharma Co. Can Solicit Votes On Ch. 11 Plan
- Monsanto Can't Bring EPA's Latest Report Into Roundup Trial
- Teary Plaintiff Tells Jury About Painful Cancer In J&J Talc Trial
- MabVax Therapeutics Lines Up $3.7M Ch. 11 Asset Sale
- Judge Questions United's Bid For New Pay-For-Delay Experts
- Amarin Says Attys 'On Speed Dial' After Ending Omega-3 Suits
- Apotex, Fresenius Kabi Settle Amgen's Cancer Drug IP Suit
- Ill. Sterilization Plant Can't Fight Closure In Federal Court
- Aralez Ch. 11 Liquidation Plan Gets Court's Approval
- Pomerantz Nabs Lead In Aveo Pharma Stock-Drop Suit
- Avenatti Blasts Class Counsel 'Hijack' In Surgical Gown Case
- 'Lack Of Clairvoyance' On Tax Audit Isn't Fraud, Perrigo Says
- Takeda Says Orexigen's Ch. 11 Plan Exposes It To $6M Claim
- Methods For Using Natural Compounds Can Be Patent-Eligible
- GNC Misleads Consumers On FDA Approval, Suit Says
- BioScrip To Pay $1M To End Probe Into Unauthorized Refills
- An Overview Of The Debate Over Litigation Finance Disclosure
- J&J Says Investors' Baby Powder Claims Already Disproven
- Law360 Reveals Titans Of The Plaintiffs Bar
- Rockford, Ill., Drug Antitrust Suit Beats Renewed Challenge
- One Sentence Ends Amgen Blockbuster's Reign, Judge Says
- St. Jude's Heart Valve Patent Challenges Get Mixed Results
- Alifax Wins $6.5M In Dispute Over Blood Testing Trade Secret
- Conviction Of Insys Execs Will Embolden Gov't In Opioid Fight
- Magistrate Details 'Cautionary Tale' Of Case-Ending Fraud
- Abbvie Investor Seeks Records On Alleged Humira Kickbacks
- Stryker Corp. Says XL Can't Blame Judge For Settlement
- Colgate Rips 'Disparaging' Sanctions Bid In ERISA Suit
- 16 Firms To Steer Packed Lineup Of IPOs Dominated By Uber
- Allergan Says Drug Buyers Trying To Delay Case 'Indefinitely'
- VA Misled Losing Bidder In Talks Over $22.6M Deal
- 2 New Efforts To Clarify Employee Cannabis Drug Testing
- DLA Piper Snags SF Real Estate Partner From Paul Hastings
- Recently Confirmed Judge Up For 3rd Circ. Promotion
- Fed. Circ. Upholds Opana Patent Amid Generic Challenge
- Supplement Co. Says FDA Crackdown On Stimulant Unlawful
- Abraham, Entwistle Seek $5.6M Atty Fees For Alere Deal
- Gene Therapy Policies Can Strike An Ethical Balance
- Obviousness Analysis Trends In Pharma Patent Cases
- Deals Rumor Mill: SoftBank, Louis Dreyfus, Shell
- GlaxoSmithKline Hit With $89.7M Verdict For Inhaler IP
- Merck Sues To Nix Mylan's Plans For Diabetes Generic
- States Say They Can Show Conspiracy In Generic Drug MDL
- New FDA Boss Details Wide-Ranging Enforcement Plan
- FDA Won't Ban Breast Implants Linked To Cancer
- Sheppard Mullin Snags Knobbe Martens Life Sciences IP Duo
- 1 Firm Edges Ahead Of Peers In Resurgent April For IPOs
- Minerva's Retrial Bid Nixed In NovaSure Patent Fight
- Hospital Won't Get Redo In Suit Clearing Generic Pepcid
- Eisai Wants Aurobindo's Generic Weight Loss Drug Blocked
- Deadline Won't Stop Med Mal Suit Against Quest Diagnostics
- Ex-NECC Pharmacists Guilty Of Role In Fake Shipments
- Ex-Insys Execs Found Guilty In RICO Opioid Bribe Scheme
- Franchising In The Cannabis Industry Begins To Light Up
- McKesson Pays $37M To Settle West Virginia's Opioid Suit
- A Tool For Budgeting Corporate Innovation Programs
- How To Identify And Deal With Narcissists In Law
- Clint Eastwood's Patent Investments Suit Tossed For Now
- Fed. Circ. Backs ITC's Refusal To Probe False Ad Claims
- Fed. Circ. OKs 'Unusual' $1.3M Fees Bill On Failed IP Suit
- SEC Must Decide On Teva Whistleblower Award, DC Circ. Told
- Judge Says TridentUSA Ch. 11 Plan OK If Probe Info Added
- Insys Jury Question Could Indicate Conviction On The Way
- Ocular Shakes Investor Suit Over FDA Approval Of Eye Drug
- PTAB Axes Another Antecip Bone Treatment Patent
- Pharma Co. Says Bidders Showing Interest In Ch. 11 Sale